Skip to main content
Top
Published in: BMC Gastroenterology 1/2024

Open Access 01-12-2024 | Ulcerative Colitis | Research

Transcriptional landscape of intestinal environment in DSS-induced ulcerative colitis mouse model

Authors: Yuefei Wen, Chenyang Li, Peng Huang, Zhigang Liu, Yanjun He, Bin Liu

Published in: BMC Gastroenterology | Issue 1/2024

Login to get access

Abstract

Ulcerative colitis (UC) is a chronic inflammatory disease that targets the colon and has seen an increasing prevalence worldwide. In our pursuit of new diagnostic and therapeutic approaches for UC, we undertook a sequencing of colons from UC mouse models. We focused on analyzing their differentially expressed genes (DEGs), enriching pathways, and constructing protein-protein interaction (PPI) and Competing Endogenous RNA (ceRNA) networks. Our analysis highlighted novel DEGs such as Tppp3, Saa3, Cemip, Pappa, and Nr1d1. These DEGs predominantly play roles in pathways like cytokine-mediated signaling, extracellular matrix organization, extracellular structure organization, and external encapsulating structure organization. This suggests that the UC pathogenesis is intricately linked to the interactions between immune and non-immune cells with the extracellular matrix (ECM). To corroborate our findings, we also verified certain DEGs through quantitative real-time PCR. Within the PPI network, nodes like Stat3, Il1b, Mmp3, and Lgals3 emerged as significant and were identified to be involved in the crucial cytokine-mediated signaling pathway, which is central to inflammation. Our ceRNA network analysis further brought to light the role of the Smad7 Long non-coding RNA (lncRNA). Key MicroRNA (miRNAs) in the ceRNA network were pinpointed as mmu-miR-17-5p, mmu-miR-93-5p, mmu-miR-20b-5p, mmu-miR-16-5p, and mmu-miR-106a-5p, while central mRNAs included Egln3, Plagl2, Sema7a, Arrdc3, and Stat3. These insights imply that ceRNA networks are influential in UC progression and could provide further clarity on its pathogenesis.
In conclusion, this research deepens our understanding of UC pathogenesis and paves the way for potential new diagnostic and therapeutic methods. Nevertheless, to solidify our findings, additional experiments are essential to confirm the roles and molecular interplay of the identified DEGs in UC.
Appendix
Available only for authorised users
Literature
3.
go back to reference Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. In: StatPearls. Treasure Island: StatPearls Publishing 2022, StatPearls Publishing Copyright © LLC.; 2022. Malik TF, Aurelio DM. Extraintestinal Manifestations of Inflammatory Bowel Disease. In: StatPearls. Treasure Island: StatPearls Publishing 2022, StatPearls Publishing Copyright © LLC.; 2022.
31.
36.
go back to reference te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJW, Hommes DW, et al. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(3):325–30. https://doi.org/10.1002/ibd.20079.CrossRef te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJW, Hommes DW, et al. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(3):325–30. https://​doi.​org/​10.​1002/​ibd.​20079.CrossRef
Metadata
Title
Transcriptional landscape of intestinal environment in DSS-induced ulcerative colitis mouse model
Authors
Yuefei Wen
Chenyang Li
Peng Huang
Zhigang Liu
Yanjun He
Bin Liu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2024
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-024-03128-8

Other articles of this Issue 1/2024

BMC Gastroenterology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine